Drug intelligence / Profile preview

Shu-Gan-Hua-Zhi prescription

Development stage: Preclinical
Lead developer: Shenyang Sixth People's Hospital
Administration: Oral

Overview

Shu-Gan-Hua-Zhi is a Traditional Chinese Medicine (TCM) herbal prescription under clinical investigation for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and related metabolic disorders. Developed and sponsored by The Sixth People's Hospital of Shenyang, the formula is designed to address the TCM patterns of liver qi stagnation and damp-heat, which correspond to hepatic fat accumulation and metabolic syndrome. It is being evaluated for its ability to improve liver function, reduce steatosis, and manage comorbidities such as type 2 diabetes mellitus and viral hepatitis.

Other names: Shu-Gan-Hua-Zhi

Beyond the preview

Go deeper on Shu-Gan-Hua-Zhi prescription.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shu-Gan-Hua-Zhi prescription.

Explore the full profile